Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Diabetes Care 30:e108 2007
DOI: 10.2337/dc07-1196
© 2007 by the American Diabetes Association
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gurgel, L. C.
Right arrow Articles by Moisés, R. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gurgel, L. C.
Right arrow Articles by Moisés, R. S.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Online Letters: Observations

Sulfonylrea Treatment in Permanent Neonatal Diabetes Due to G53D Mutation in the KCNJ11 Gene

Improvement in glycemic control and neurological function

Lucimary C. Gurgel, MD1, Felipe Crispim, BSC1, Maria Helena S. Noffs, MSC2, Erich Belzunces, BSC2, Marcio A. Rahal, MD2 and Regina S. Moisés, MD, PHD1

1 Department of Endocrinology, Federal University of São Paulo, São Paulo, Brazil
2 Department of Neurology, Federal University of São Paulo, São Paulo, Brazil

Address correspondence to Regina S. Moisés, MD, PhD, Universidade Federal de São Paulo, Rua Botucatu, 740-2o, Andar, 04034-970 São Paulo, Brazil. E-mail: rmoises@endocrino.epm.br

The first 20% of the full text of this article appears below.

Previous studies have reported the successful switch from insulin to sulfonylrea therapy in some patients who have neonatal diabetes due to KCNJ11 mutations (1); however, data on adults are limited (2,3). Also, it has not yet been determined whether neurological symptoms can be improved by the action of sulfonylrea therapy.

Here, we report the glycemic and neurological responses in an adult patient with the G53D mutation in the KCNJ11 gene who was transferred from insulin to sulfonylurea.

A 26-year-old male patient was diagnosed with diabetes in . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2007 by the American Diabetes Association.